By Lorna Patrick, Chief Operating Officer, Upperton In the world of outsourced drug development and manufacturing, risk management is often discussed as if it were a standard, universally embedded ...
STAT: FDA’s new guidance on AI in drug development centers the risk introduced by the technology
FDA’s new guidance on AI in drug development centers the risk introduced by the technology
RAPS: Risk Evaluation and Mitigation Strategies for US Drug Development, Second Edition (e-book)
Risk Evaluation and Mitigation Strategies for US Drug Development, Second Edition (e-book)
SiliconANGLE: ArcaScience raises $7M to expand AI benefit risk platform in drug development
ArcaScience raises $7M to expand AI benefit risk platform in drug development
The drug development process necessitates the comprehensive evaluation of a candidate’s therapeutic benefits alongside its potential risks. Benefit–risk assessments are central to this endeavour, ...
Later this month, the US Food and Drug Administration (FDA) will formally launch its Drug Risk Management Board (DRMB) to coordinate safety activities among offices, Center for Drug Evaluation and ...
JD Supra: What is the IP Risk Profile in AI Drug Discovery?
The scientific benefits and legal risks of AI-driven drug discovery are consequential. But recent IP law decisions allude to a general concept that IP rights will not be awarded if AI completely or ...
How to Convince Your Boss They Need a Coach Managing up Digital Article Marlo Lyons Five steps to frame the conversation using strategy, empathy, and restraint.
If you read nothing else on managing people, read this book. We've chosen a new selection of current and classic "Harvard Business Review" articles that...
You’re managing more people than ever with far less support. Responsibilities keep multiplying, but the resources haven’t. And even though you’re supposed to be thinking strategically and ...